Health TrialsbyHealthPanel

Intensive Care Outcome Prediction Using Admission Carbohydrate-deficient Transferrin

ConditionsIntensive Care (ICU)Critical IllnessAlcohol Misuse
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMedical University of Vienna

About this trial

The goal of this observational study is to learn whether hazardous alcohol consumption, measured objectively by carbohydrate-deficient transferrin (CDT) levels at intensive care unit (ICU) admission, is associated with worse outcomes in critically ill patients. The main question it aims to answer is:

Do elevated CDT levels at ICU admission predict increased short-term mortality and adverse clinical outcomes in adult non-traumatic ICU patients? Participants admitted to the intensive care unit via the emergency department will have CDT levels measured as part of the study. Researchers will then collect and analyze clinical data, including mortality, duration of mechanical ventilation, delirium, ICU length of stay, renal replacement therapy, and ICU readmission rates, during hospitalization and follow-up.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

all patients ≥ 18 admitted to the Department of Emergency Medicine and subsequently transferred to an in-house intensive care unit (ICU)

Disqualifiers

Patients transferred to other hospital departments prior to completion of intensive care

Patients admitted directly to the ICU without passing the ED

Patients admitted to intermediate care units

Patients with pre-existing or newly diagnosed hepatic cirrhosis

Trial population

Study participants will be selected from adult patients admitted to the Department of Emergency Medicine who are subsequently transferred to an in-house intensive care unit (ICU). The study population consists of critically ill non-traumatic ICU patients receiving routine emergency and intensive care treatment.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Carbohydrate-Deficient Transferrin (CDT) Measurement

    Diagnostic test

    Carbohydrate-deficient transferrin (CDT) measurement is performed at ICU admission as an objective biomarker of sustained hazardous alcohol consumption during the previous 1-3 weeks. CDT values are obtained from routinely collected blood samples in adult non-traumatic ICU patients admitted via the emergency department. The study is purely observational and does not involve administration of a therapeutic intervention or changes to standard clinical care. CDT levels are analyzed in relation to outcomes including 30-day mortality, ICU length of stay, mechanical ventilation, delirium, renal replacement therapy, and ICU readmission.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

The primary outcome of the study is 30-day all-cause mortality in ICU patients.

30-day all-cause mortality is defined as death from any cause occurring within 30 days after ICU admission. Mortality status will be assessed using patient medical records and, if unavailable, through the Austrian "Zentrales Personenstandsregister" (Central Civil Status Register), which documents registered deaths. Outcomes will be compared between patients with elevated and non-elevated carbohydrate-deficient transferrin (CDT) levels measured at ICU admission.

Time frame
From ICU admission to 30 days after ICU admission

Secondary outcomes

1

In-hospital mortality

Death from any cause occurring during the index hospital stay.

Time frame
From hospital admission to hospital discharge evaluated 6 Months after study inclusion
2

ICU length of stay

Duration of stay in the intensive care unit, measured in days from ICU admission to ICU discharge.

Time frame
From ICU admission to ICU discharge evaluated 6 Months after study inclusion
3

Duration of mechanical ventilation

Total duration of mechanical ventilation during the ICU stay, measured in hours or days.

Time frame
From initiation of mechanical ventilation to successful discontinuation during ICU stay evaluated 6 Months after study inclusion
4

Illness severity score

Severity of illness assessed using TISS(-A), with a higher score signaling higher severity

Time frame
Evaluated from the documentation 6 Months after study inclusion

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Medical University of Vienna

Lead sponsor

Source ClinicalTrials.gov
Apply now